WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Pentagon vows to keep weapons moving to Ukraine as Kyiv faces a renewed assault by Russia
Chinese books attract global attention at Italy's biggest book fair
AP weekly sports photo gallery
Britain's police 'aren't interested' in tackling shoplifting anymore, Marks & Spencer's boss claims
Yu Darvish extends scoreless innings streak to 25 in Padres' 9
California's wealthiest farming family threatens to reshape small town with new mega
FBI, Homeland Security warn of possible threats to LGBTQ events, including Pride Month activities
Argentina reports its first single
Socialite Jasmine Hartin enjoys beach snuggle with electrician hunk
Assaults on law enforcement in the US reached a 10
Burglar hurled stolen mobile phones at police from the top of 60ft high roof during nine
Wife is spared jail for stabbing her husband for falling asleep while she was talking to him